Phase III trial shows improved survival with TAS-102 in metastatic colorectal cancer refractory to standard therapies
Saturday, June 28, 2014 - 21:01
in Health & Medicine
The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said.